INTRODUCTION: Carbon-11-labeled (+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol ([(11)C]-(+)-PHNO) is a dopamine D2/D3 agonist radioligand that is currently used to image the high-affinity state of dopamine receptors in humans with positron emission tomography (PET). The present study reports the preparation and evaluation of fluorinated (+)-PHNO derivatives. METHODS: Five fluorinated (+)-PHNO derivatives were synthesized and tested in vitro for inhibition of binding of [(3)H]domperidone in homogenates of rat striatum and inhibition of binding to [(3)H]-(+)-PHNO in homogenates of human-cloned D2Long receptors in Chinese hamster ovary cells and rat striatum. Radiolabeling with fluorine-18 was carried out for the most promising candidate, N-fluoropropyl-(+)-HNO (F-PHNO), and ex vivo biodistribution and autoradiography studies with this radiopharmaceutical were performed in rodents. RESULTS: (+)-PHNO and the fluorinated analogs inhibited binding of [(3)H]domperidone and [(3)H]-(+)-PHNO to the high- and low-affinity states of dopamine D2 receptors, consistent with D2 agonist behavior. The average dissociation constant at the high-affinity state of D2, K(i)(High), was 0.4 nM for F-PHNO and proved to be equipotent with (+)-PHNO (0.7 nM). All other fluorinated derivatives were significantly less potent (K(i)(High)=2-102 nM). The most promising candidate, F-PHNO, was labeled with fluorine-18 in 5% uncorrected radiochemical yield, with respect to starting fluoride. Ex vivo biodistribution and autoradiography studies in rodents revealed that [(18)F]F-PHNO rapidly enters the rodent brain. However, this radiotracer does not reveal specific binding in the brain and is rapidly cleared. CONCLUSIONS: Five novel dopamine D2/D3 agonists based on (+)-PHNO were synthesized and evaluated in vitro. F-PHNO was shown to behave as a potent D2 agonist in vitro and was therefore radiolabeled with fluorine-18. Despite the promising in vitro pharmacological profile, [(18)F]F-PHNO did not display in vivo behavior suitable to image dopaminergic receptor expression using PET.
INTRODUCTION:Carbon-11-labeled (+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol ([(11)C]-(+)-PHNO) is a dopamine D2/D3 agonist radioligand that is currently used to image the high-affinity state of dopamine receptors in humans with positron emission tomography (PET). The present study reports the preparation and evaluation of fluorinated (+)-PHNO derivatives. METHODS: Five fluorinated (+)-PHNO derivatives were synthesized and tested in vitro for inhibition of binding of [(3)H]domperidone in homogenates of rat striatum and inhibition of binding to [(3)H]-(+)-PHNO in homogenates of human-cloned D2Long receptors in Chinese hamster ovary cells and rat striatum. Radiolabeling with fluorine-18 was carried out for the most promising candidate, N-fluoropropyl-(+)-HNO (F-PHNO), and ex vivo biodistribution and autoradiography studies with this radiopharmaceutical were performed in rodents. RESULTS:(+)-PHNO and the fluorinated analogs inhibited binding of [(3)H]domperidone and [(3)H]-(+)-PHNO to the high- and low-affinity states of dopamine D2 receptors, consistent with D2 agonist behavior. The average dissociation constant at the high-affinity state of D2, K(i)(High), was 0.4 nM for F-PHNO and proved to be equipotent with (+)-PHNO (0.7 nM). All other fluorinated derivatives were significantly less potent (K(i)(High)=2-102 nM). The most promising candidate, F-PHNO, was labeled with fluorine-18 in 5% uncorrected radiochemical yield, with respect to starting fluoride. Ex vivo biodistribution and autoradiography studies in rodents revealed that [(18)F]F-PHNO rapidly enters the rodent brain. However, this radiotracer does not reveal specific binding in the brain and is rapidly cleared. CONCLUSIONS: Five novel dopamine D2/D3 agonists based on (+)-PHNO were synthesized and evaluated in vitro. F-PHNO was shown to behave as a potent D2 agonist in vitro and was therefore radiolabeled with fluorine-18. Despite the promising in vitro pharmacological profile, [(18)F]F-PHNO did not display in vivo behavior suitable to image dopaminergic receptor expression using PET.
Authors: Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach Journal: Synapse Date: 2010-06 Impact factor: 2.562
Authors: Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach Journal: Synapse Date: 2009-09 Impact factor: 2.562
Authors: Sjoerd J Finnema; Vladimir Stepanov; Ryuji Nakao; Anna W Sromek; Tangzhi Zhang; John L Neumeyer; Susan R George; Philip Seeman; Michael G Stabin; Cathrine Jonsson; Lars Farde; Christer Halldin Journal: J Nucl Med Date: 2014-05-01 Impact factor: 10.057
Authors: Anna W Sromek; Shaohui Zhang; Vamsidhar Akurathi; Alan B Packard; Wei Li; David Alagille; Thomas J Morley; Ronald Baldwin; Gilles Tamagnan; John L Neumeyer Journal: J Labelled Comp Radiopharm Date: 2014-11-17 Impact factor: 1.921
Authors: Anna W Sromek; Yu-Gui Si; Tangzhi Zhang; Susan R George; Philip Seeman; John L Neumeyer Journal: ACS Med Chem Lett Date: 2011-03-10 Impact factor: 4.345
Authors: Vladimir Shalgunov; Jan-Peter van Wieringen; Henk M Janssen; P Michel Fransen; Rudi A J O Dierckx; Martin C Michel; Jan Booij; Philip H Elsinga Journal: EJNMMI Res Date: 2015-07-25 Impact factor: 3.138
Authors: Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga Journal: Med Res Rev Date: 2018-11-18 Impact factor: 12.944